Results of 6 clinical studies have been
published in peer-reviewed journals, including
the American Journal of Hypertension. Resperate
delivers an average 14/9 mmHg sustained
blood pressure reduction within 8 weeks
of proper use (15 minutes a day, 3-4 times
per week). The Scientific Advisory Board
for Resperate includes many of the world's
leading hypertension experts, including
past presidents of the American, European
and International Societies of Hypertension.
The underlying physiological mechanism of
action of Low Frequency Respiratory Pacing
technology, as deployed in Resperate, was
recently discussed in the AHA Hypertension
Primer, Third Edition textbook. A reprint
of the relevant chapter is available by
request. |
